INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering
SARASOTA, Fla., March 27, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fe
INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market
SARASOTA, Fla., March 24, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fe
INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute
Accretive acquisition expected to add significant scale to INVO's operations Contributes over $5 million in incremental
INVO Bioscience Enters Distribution Agreement for Taiwan
SARASOTA, Fla., Jan. 5, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fert
INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center
Shelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa-based INVO Center.The cu
First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology
Patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOce
INVO Bioscience Reports Third Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Nov. 14, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO
INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Nov.
INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo
- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet